Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Insider Purchases $54,000.00 in Stock

Share on StockTwits

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) insider Lonnel Coats acquired 40,000 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were bought at an average cost of $1.35 per share, with a total value of $54,000.00. Following the purchase, the insider now owns 87,695 shares of the company’s stock, valued at approximately $118,388.25. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Lonnel Coats also recently made the following trade(s):

  • On Friday, August 16th, Lonnel Coats acquired 37,000 shares of Lexicon Pharmaceuticals stock. The shares were bought at an average cost of $1.35 per share, with a total value of $49,950.00.

NASDAQ:LXRX opened at $1.36 on Friday. The firm has a market cap of $140.28 million, a PE ratio of -1.19 and a beta of 0.77. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $11.88. The business has a 50 day moving average price of $3.61 and a 200-day moving average price of $5.40.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.13). The company had revenue of $9.68 million during the quarter, compared to the consensus estimate of $28.52 million. The firm’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.33) EPS. As a group, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.8 EPS for the current fiscal year.

A number of analysts have recently weighed in on LXRX shares. Citigroup dropped their price objective on Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, July 30th. BidaskClub lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 19th. Stifel Nicolaus lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the company from $10.00 to $4.00 in a research note on Monday, July 29th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $7.63.

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of Lexicon Pharmaceuticals by 940.2% during the first quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 8,979 shares in the last quarter. Wealth & Pension Services Group Inc. bought a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $60,000. Trexquant Investment LP bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $92,000. Metropolitan Life Insurance Co. NY raised its holdings in shares of Lexicon Pharmaceuticals by 409.3% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 11,862 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $105,000. Institutional investors own 97.12% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

iShares MSCI USA ESG Select Scl Indx Fnd  Shares Sold by Massmutual Trust Co. FSB ADV
iShares MSCI USA ESG Select Scl Indx Fnd Shares Sold by Massmutual Trust Co. FSB ADV
Massmutual Trust Co. FSB ADV Trims Stock Position in ISHARES TR/CORE DIVID GR ETF
Massmutual Trust Co. FSB ADV Trims Stock Position in ISHARES TR/CORE DIVID GR ETF
EZCORP  Stock Price Down 11.5%
EZCORP Stock Price Down 11.5%
Opera  Stock Price Down 7.5%
Opera Stock Price Down 7.5%
Lexicon Pharmaceuticals  Trading Down 9.2%
Lexicon Pharmaceuticals Trading Down 9.2%
Hi-Crush  Trading Down 6.8%
Hi-Crush Trading Down 6.8%


© 2006-2019 Ticker Report